Can Cologuard replace a colonoscopy if I have symptoms?

No. The FDA label says Cologuard is a screening test for average-risk adults with no symptoms. It is not a replacement for a diagnostic colonoscopy. Rectal bleeding, a change in bowel habits, or unexplained weight loss call for a colonoscopy, not a stool test.

What is the Cologuard false positive rate?

In the DeeP-C trial, 13.4% of people without cancer or advanced polyps still tested positive. Among people with a completely normal colonoscopy, about 10% tested positive. The newer Cologuard Plus lowered that to roughly 7% in the BLUE-C trial.

If my Cologuard is negative, am I in the clear?

Mostly, but not completely. Cologuard missed 8% of cancers and 58% of advanced precancerous polyps in its approval trial. A negative result means you should repeat the test in 3 years, or switch to another screening method. It does not mean your colon has been examined.

Is Cologuard more accurate than FIT?

For finding disease, yes. In DeeP-C, Cologuard found 92% of cancers versus 74% for FIT, and 42% of advanced polyps versus 24% for FIT. FIT had fewer false positives (95% specificity versus 87%). FIT is repeated every year, which narrows the gap over time.

Does a positive Cologuard followed by a normal colonoscopy mean something was missed?

Usually not. The ACG says asymptomatic people with a positive stool DNA test and a negative high-quality colonoscopy do not need extra testing such as upper endoscopy or CT. You go back to the normal screening schedule unless symptoms or other tests point elsewhere.

How Accurate Is Cologuard Compared With a Colonoscopy?

The short answer: Cologuard is good at finding cancer and weak at finding the polyps that become cancer. In its FDA approval trial, it detected 92.3% of colorectal cancers but only 42.4% of advanced precancerous lesions, and 13.4% of people without either got a false positive. Colonoscopy sees the colon directly and removes polyps in the same visit, though even colonoscopy misses about 1 in 4 small adenomas. A positive Cologuard always leads to a colonoscopy anyway.

What do the accuracy numbers actually measure?

Two numbers describe any screening test. Sensitivity is the share of people with disease that the test flags. Specificity is the share of people without disease that the test correctly clears. A test with 90% specificity gives a false positive to 10% of healthy people.

Cologuard (the brand name for the multitarget stool DNA test, or mt-sDNA) is measured against colonoscopy. In its trials, every participant did both tests, and the colonoscopy result was treated as the truth. That design matters. It means Cologuard can never be scored as more accurate than the colonoscopy it was compared with. The real question is how much of what a colonoscopy finds a stool test can catch.

Cologuard also reports only a positive or negative result. Colonoscopy shows where a lesion is, how big it is, and treats most polyps on the spot. Our screening options overview compares every approved test. This article goes deeper on the head-to-head numbers.

How accurate is Cologuard for finding cancer?

The pivotal DeeP-C trial, published in the New England Journal of Medicine in 2014, enrolled 9,989 average-risk adults who took Cologuard, a FIT, and a colonoscopy. Colonoscopy found 65 cancers. Cologuard flagged 60 of them, a sensitivity of 92.3%. FIT flagged 48, or 73.8%. The FDA approval summary reports the same figures and notes a 95% confidence interval of 83.0% to 97.5% for cancer sensitivity.

The trade-off was specificity. Among people with no cancer and no advanced polyp, Cologuard was negative 86.6% of the time, versus 94.9% for FIT. Among people with a fully normal colonoscopy, Cologuard specificity was 89.8%. Roughly 1 in 10 people with a clean colon still got a positive result and a referral for colonoscopy.

The next-generation test, Cologuard Plus, was designed to fix that problem. The BLUE-C trial, published in the New England Journal of Medicine in 2024, tested 20,176 adults. Cancer sensitivity was 93.9%, and specificity for advanced neoplasia rose to 90.6%. Specificity among people with a negative or non-neoplastic colonoscopy was 92.7%. FIT in the same study found 67.3% of cancers with 94.8% specificity. The FDA approved Cologuard Plus for average-risk adults 45 and older on October 4, 2024, according to the manufacturer's announcement.

The USPSTF evidence review pools these data into a cancer sensitivity of 0.93 and specificity of 0.84 for stool DNA-FIT. In plain terms, Cologuard catches about 9 in 10 cancers on a single test.

How well does Cologuard find precancerous polyps?

This is where the two tests separate. Colorectal cancer usually grows from an adenoma or sessile serrated lesion over years. Screening prevents cancer by finding and removing those lesions before they turn. Our guide to colon polyps explains which types matter most.

In DeeP-C, colonoscopy found 760 advanced precancerous lesions. Cologuard detected 42.4% of them. FIT detected 23.8%. In BLUE-C, Cologuard Plus detected 43.4% of 2,144 advanced precancerous lesions, and FIT detected 23.3%. The USPSTF review puts stool DNA-FIT sensitivity for advanced adenomas at 0.43.

So Cologuard misses more than half of advanced polyps on any single test. It performs better than FIT, and it is designed to be repeated, so some missed lesions are caught on the next round. But a person with a negative Cologuard has not had their polyps found or removed. That is the core difference. Colonoscopy is the only screening test that removes what it finds.

For comparison, the ECLIPSE trial of a blood-based test, also in the New England Journal of Medicine in 2024, found 13.2% of advanced precancerous lesions.

How accurate is colonoscopy itself?

Colonoscopy is the reference standard, but it is not perfect. The USPSTF review cites colonoscopy sensitivity of 0.89 to 0.95 for adenomas 10 mm or larger.

The best measure of what colonoscopy misses comes from tandem studies, where a second colonoscopy immediately follows the first. A 2019 meta-analysis in Gastroenterology pooled 43 studies and more than 15,000 tandem colonoscopies. The pooled miss rate was 26% for adenomas overall, 9% for advanced adenomas, and 27% for serrated polyps. Flat adenomas were missed 34% of the time. Miss rates fell with adequate bowel preparation and with higher adenoma detection rates.

Colonoscopy quality varies by doctor and by prep. The 2021 ACG guideline tells endoscopists to track their adenoma detection rate, reach the cecum in at least 95% of screening exams, and spend at least 6 minutes inspecting on withdrawal. A clean prep is your part of the job. Our prep guide covers how to get there. Even with those misses, colonoscopy still finds far more advanced lesions than any stool test. The 42% Cologuard figure is measured against colonoscopy's findings, not against the true total.

What does a positive Cologuard result mean?

It means you need a colonoscopy. The FDA label states that a positive result "may indicate the presence of colorectal cancer or advanced adenoma and should be followed by diagnostic colonoscopy." The American Cancer Society says any abnormal non-colonoscopy screening test "should be followed up with a timely colonoscopy."

A positive result does not mean you have cancer. In DeeP-C, 13.4% of participants with no cancer and no advanced polyp still tested positive, so most positive results came from people without advanced disease. Real-world data show the same pattern. A Mayo Clinic study of 1,558 patients who had a colonoscopy after a positive mt-sDNA test found some kind of colorectal neoplasia in 67%, advanced neoplasia in 28%, and cancer in 1%. So roughly 1 in 3 positive tests leads to a finding that matters, and about 1 in 100 leads to a cancer diagnosis.

If the follow-up colonoscopy is normal, the ACG guideline says asymptomatic patients should not undergo additional testing such as upper endoscopy, CT, or an early repeat colonoscopy. The positive stool test is treated as a false positive, and you return to the standard screening schedule.

One more limit. Cologuard is approved only for people at average risk with no symptoms. If you have rectal bleeding, a change in bowel habits, or unexplained weight loss, you need a diagnostic colonoscopy rather than a screening test. symptom.md can help you sort out which symptoms need prompt attention.

Why is Cologuard repeated every 3 years and colonoscopy every 10?

The intervals reflect the accuracy gap. The CDC lists the stool DNA test as "done once every 3 years" and colonoscopy as "every 10 years" for people without increased risk. The USPSTF gives stool DNA-FIT an interval of every 1 to 3 years and colonoscopy every 10 years. The ACG suggests mt-sDNA every 3 years and recommends colonoscopy every 10 years, with FIT every year. The ACS matches those intervals.

A normal colonoscopy earns a 10-year interval because the whole colon was inspected and any polyps were removed. A negative Cologuard earns 3 years because more than half of advanced polyps may still be there. Repeating the test gives it more chances to catch a slowly growing lesion. The ACG also notes that modeling studies found annual FIT and 10-year colonoscopy more effective and less costly than stool DNA every 3 years.

The bottom line

Cologuard finds about 92% to 94% of colorectal cancers on a single test, and the newer Cologuard Plus produces fewer false positives. That makes it a reasonable screening choice for a person who will not get a colonoscopy. But it finds fewer than half of advanced precancerous polyps, and it cannot remove any of them. Colonoscopy misses some polyps too, especially small and flat ones, yet it remains the only test that both finds and treats. Every positive stool test ends in a colonoscopy, and about 1 in 3 of those exams finds advanced disease. Pick the test you will do, and do it on schedule.

Last updated: September 2026. This article is for informational purposes only and does not constitute medical advice. Talk with your doctor about which colorectal cancer screening test fits your risk and preferences.